• Important Safety
    Information
  • Prescribing
    Information
    • Gvoke Hypopen
    • Gvoke PFS
    • Gvoke Kit
  • Patient Site
Gvoke® PFS (glucagon injection) Pre-Filled Syringe and Gvoke HypoPen® logos
Menu
Close
Gvoke® (glucagon injection) homepage
HOME
WHAT IS GVOKE? WHY PRESCRIBE GVOKE? GLUCAGON GUIDELINES
DEMONSTRATED EFFICACY PHARMACOKINETICS SAFETY
DOSING
FINANCIAL SUPPORT & ACCESS RESOURCES FOR YOUR PRACTICE EVENTS SIGN UP CONTACT A REPRESENTATIVE
SIGN UP FOR MORE INFORMATION CONTACT A REPRESENTATIVE
Gvoke HypoPen Gvoke PFS Gvoke Kit
PATIENT SITE
Stay Informed About Gvoke Request a Demo Device Contact a Representative

The information contained on this site is intended for US healthcare professionals only. Click "OK" if you are a healthcare professional.

Sitemap
  • HOME
ABOUT GVOKE
  • WHAT IS GVOKE?
  • WHY PRESCRIBE GVOKE?
  • GLUCAGON GUIDELINES
EFFICACY & SAFETY
  • DEMONSTRATED EFFICACY
  • PHARMACOKINETICS
  • SAFETY
  • DOSING
RESOURCES & SUPPORT
  • FINANCIAL SUPPORT & ACCESS
  • RESOURCES FOR YOUR PRACTICE
  • EVENTS
  • SIGN UP
  • REQUEST A DEMO
  • CONTACT A REPRESENTATIVE

We use cookies to help personalize your experience. For more information on how we use cookies and similar technologies, and how you can change your settings, please see our Privacy Policy.

close
Read More

INDICATION AND SAFETY SUMMARY

INDICATION AND IMPORTANT SAFETY INFORMATION

GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.

Close

INDICATION AND IMPORTANT SAFETY INFORMATION

GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications

GVOKE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure, insulinoma because of the risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.

Warnings and Precautions

GVOKE is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GVOKE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously.

Allergic reactions have been reported with glucagon. These include generalized rash, and in some cases, anaphylactic shock with breathing difficulties and hypotension. GVOKE is contraindicated in patients with a prior hypersensitivity reaction.

GVOKE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia, may not have adequate levels of hepatic glycogen for GVOKE administration to be effective. Patients with these conditions should be treated with glucose.

Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported postmarketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.

Adverse Reactions

Most common (≥5%) adverse reactions associated with GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.

Drug Interactions

Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE. In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin.

Please see full Prescribing Information for Gvoke.

  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Privacy Shield Policy
  • Financial Conflict of Interest Policy
  • Sitemap

Gvoke® , Gvoke HypoPen® , Xeris Pharmaceuticals® , and their associated logos are trademarks of Xeris Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

Copyright ©2022 Xeris Pharmaceuticals, Inc. All rights reserved. US-GVK-19-00116v14  07/22

Xeris Pharmaceuticals, Inc. logo

You are now leaving GvokeGlucagon.com

Would you like to continue?

YES NO
Previous Next